Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

Outlook Therapeutics, Inc.’s OTLK share price has dipped by 6.40%, which has investors questioning if this is right time to ...

With fiscal 2025 being a low base year due to losses, earnings per share are forecast to more than double by financial year ...

Cardiff Oncology is entering a pivotal stage with a strong cash runway and compelling early data in first-line RAS-mutant ...